About the Program
The Department of Pathology offers a one-year fellowship in Cancer Biomarker Pathology. The program provides fellows with expertise in integrating traditional microscopic diagnostic and technical skills for the discovery and validation of clinically useful pathology biomarkers for cancer patients. The program also will adequately prepare pathology trainees for a successful career in academic medicine.
The cancer biomarker pathology fellow will identify a specific cancer type for more detailed study, and an appropriate program faculty supervisor. The fellow will participate in traditional microscopic sign-out of cases in this subspecialty field.
Available pathology subspecialties at MD Anderson include:
- Soft tissue
For example, trainees interested in colon cancer biomarker development will participate in GI pathology clinical sign-out, and those interested in ovarian cancer biomarker discovery will participate in gynecological pathology clinical sign-out.
In addition to acquiring focused, diagnostic experience in subspecialty areas, the fellow will gain knowledge and skills in molecular techniques for cancer biomarker discovery, such as genomic technologies (cDNA microarray, PCR, qRT-PCR), proteomic technologies, tissue microarrays and protein lysate arrays.
Particular emphasis will be placed on the integration of such molecular data with established clinical and pathological indicators of tumor behavior. Trainees also will be expected to participate in relevant tumor board planning treatment conferences at MD Anderson, in which discussion of the utility of such molecular assays frequently occurs.
Upon program completion, the fellow will have gained proficiency in diagnostic pathology in his or her chosen subspecialty and in various applied genomic technologies. Such a combination will be vital to adequately prepare the next generation of academic leaders in pathology and biomarker development program.
Candidates must be board certified or eligible for certification in anatomic pathology or AP/CP. Preference will be given to applicants who are interested in a career in academic pathology.
Please check complete GME Eligibility Requirements prior to applying.
December 31, 18 months prior to the start of the training year.
Commensurate with the candidate's level of training.
Russell Broaddus, M.D., Ph.D.
Fellowship Program Director
Division of Pathology & Laboratory Medicine
UT MD Anderson Cancer Center
1515 Holcombe Blvd., Unit 085
Houston, TX 77030
For other inquiries, please contact:
For inquiries on elective rotations, please email:
For inquiries on observerships, please email:
Verification of training
Requests for verification should be sent to:
MD Anderson Cancer Center is committed to encouraging good health and staying true to our mission to end cancer. If you are applying for a GME fellowship or residency program starting on or after July 1, 2016, please be advised that MD Anderson will have instituted a tobacco-free hiring process as part of its efforts to achieve these goals. If you are offered an appointment, you will be subject to a Pre-Employment Drug Screen for tobacco compounds in compliance with applicable state laws. If you do not pass the urine drug screening which includes testing for tobacco compounds, you CANNOT be appointed at MD Anderson. Should you fail to meet this contingency, MD Anderson will withdraw your offer of appointment for the academic year. You may reapply for the following academic year, but there are no guarantees that you will be offered a position as many of our programs are already filled for several years out.